Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
MVA-MERS-S 백신으로 후기 3차 면역 후 MERS-CoV-스파이크 특이적 B 세포 및 항체의 지속성
Article
[키워드] Administered
antibody
antibody isotypes
B cell
B cell response
B cells
binding
boost
booster
booster vaccination
caused
coronavirus
Coronavirus 2019
COVID-19
Cytometry
ELISA
ELISPOT
ENhance
enzyme
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
enzyme-linked immunospot
flow cytometry
Frequency
highlight
homologous
IgG
IgG ELISpot
IgG subclasses
IgG1
immune
immune persistence
immune response
immune responses
Immunity
immunization
Immunoglobulin
ImmunoSpot
increase
isotypes
late booster vaccination
long-term immunity
longitudinal analysis
memory B
memory B cells
MERS
MERS coronavirus
MERS-CoV
MERS-S
Middle East
Middle East respiratory syndrome
modified vaccinia virus
MVA-MERS-S
neutralization capacity
neutralization test
Neutralizing
Neutralizing antibodies
neutralizing antibody
persistence
Phase 1
phase 1 trial
plaque-reduction neutralization test
PRNT50
Protein
respiratory
Respiratory disease
significantly
Spike protein
syndrome
T and B cell responses
T cell
T cell responses
Vaccination strategies
Vaccine
Viral
Viral vector vaccine
[DOI] 10.1016/j.xcrm.2022.100685 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.xcrm.2022.100685 PMC 바로가기 [Article Type] Article